Search

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

EHA-SfPM Precision Medicine Meeting

EHA and SfPM (Society for Functional Precision Medicine) are proud to present the first joint meeting on Precision Medicine.

Read more

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

Read more

Horizon 2020: The European Commission proposes the successor to Framework Programme 7

Horizons 2020 will pay “particular attention to ensuring a broad approach to innovation, which is not only limited to the development of new products and services on the basis of scientific and technological breakthroughs, but which also incorporates aspects such…

Read more

Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests

In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.

Read more

The ‘i4MDS’ consortium looks to the future at its second general meeting

Feb 29 2024 Posted in Meeting reports Tagged i4MDS

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more